Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Molecular Diagnostics Market Worth 11.54 Billion USD by 2023


PUNE, India, May 24, 2018 /PRNewswire/ --

According to a new market research report "Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laboratory), Product & Service (Reagent, Software) - Global Forecast to 2023", published by MarketsandMarketstm, the global market is expected to reach USD 11.54 Billion by 2023 from USD 7.71 Billion in 2018, at a CAGR of 8.4%. The high prevalence of infectious diseases and various types of cancers, increasing awareness and acceptance of personalized medicine and companion diagnostics, growth in the biomarker identification market, and advancements in molecular techniques are some of the key factors driving the growth of this market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Browse 221 market data Tables and 38 Figures spread through 241 Pages and in-depth TOC on "Molecular Diagnostics Market"

https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html

Early buyers will receive 10% customization on this report 

Based on technology, the PCR segment is expected to account for the largest share of the market in 2018 

On the basis of technology, the market is broadly segmented into PCR, INAAT, DNA sequencing & NGS, in situ hybridization, DNA microarrays, and other technologies. The PCR segment is expected to account for the largest share of the global Molecular Diagnostics Market in 2018. The large share of this segment is attributed to the growing use of PCR in proteomics and genomics, automation of PCR instruments, and the emergence of advanced technologies like qRT-PCR.

The infectious diseases segment is expected to account for the largest share of the Molecular Diagnostics Market, by application, in 2018 

On the basis application, the market is broadly segmented into infectious diseases, oncology, genetic tests, and other applications. The infectious diseases segment is expected to account for the largest share of the global Molecular Diagnostics Market in 2018. The large share of this segment is attributed to the development of advanced assays for different diseases and conditions, significant increase in the prevalence of infectious diseases, and rising awareness about the effective use of molecular diagnostic technologies to control the occurrence and spread of infectious diseases.

Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=833

Hospital & academic laboratories are the largest end users of the Molecular Diagnostics Market 

On the basis of end user, the market is broadly segmented into hospitals and academic laboratories, reference laboratories, and other end users. The hospitals and academic laboratories segment is expected to account for the largest share of the market in 2018. The large share of this segment can primarily be attributed to the large number of diagnostic tests conducted in hospitals.

North America to dominate the Molecular Diagnostics Market in 2018 

In 2018, North America is expected to account for the largest share of the global Molecular Diagnostics Market. The large share of this region is mainly attributed to the high prevalence of infectious diseases and cancers, presence of a highly developed healthcare system and large number of leading national clinical laboratories, easy accessibility to technologically advanced instruments in the region, availability of government funds, and growing applications of molecular diagnostics in genetic disorders and cancer screening.

The key players in the global Molecular Diagnostics Market are Roche (Switzerland), Hologic (US), QIAGEN (Netherlands), Abbott (US), and Danaher (US).

Know more about the Molecular Diagnostics Market: 

https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html

About MarketsandMarketstm  

MarketsandMarketstm provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarketstm for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarketstm are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarketstm now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarketstm is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Salgarkar
MarketsandMarketstm INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]

Connect with us on LinkedIn: http://www.linkedin.com/company/marketsandmarkets


SOURCE MarketsandMarkets


These press releases may also interest you

at 10:52
MagiQ Technologies, the leader in optical sensor innovation for energy, defense, and telecom, announced today that they have successfully demonstrated the high-temperature capabilities of their fiber-optic accelerometers during extensive simulated...

at 10:52
A motion hearing in the above-named matter is scheduled to be heard on May 1, 2024 at 10:00 a.m. by videoconference.  Members of the public may observe the hearing by videoconference, by selecting the "Register to attend" link on the Tribunal's...

at 10:50
Novocure today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held...

at 10:48
Venom Blockchain and United Network have joined their strengths to create a revolutionary blockchain-powered payment infrastructure in a groundbreaking move that could redefine the future of global payments. This unique partnership aims to harness...

at 10:46
ClimeCo, the leading global decarbonization and environmental solutions company, has launched ClimeCo 4Nature, a program that offers leading sustainability-focused companies an opportunity to invest in carefully selected nature-based projects that...

at 10:40
Accredible, the world's leading digital credential platform, announced today that it has been named to TIME's World's Top EdTech Companies 2024 list. Presented by TIME and Statista Inc., the inaugural list recognizes the top companies providing...



News published on and distributed by: